ReviewAdvanced biology2026
Single-Cell Glycomics of the Pancreatic Tumor Microenvironment: Technologies, Glyco-Immune Checkpoints, and Tumor-Immune Communication.
Review in Advanced biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In this Review, we summarize recent conceptual and technological advances in single-cell glycomics, with a particular focus on emerging strategies that enable glycan-resolved analysis of tumor-immune interactions. We highlight single-cell glycan and RNA sequencing (scGR-seq), a methodology that converts glycan information into amplifiable nucleic acid signals, enabling simultaneous profiling of transcriptomes and glycomes at the single-cell level. In parallel, we introduce GlycoChat, a computational framework designed to systematically infer and visualize glycan-lectin interaction networks within the TME. Integrative application of these approaches to pancreatic ductal adenocarcinoma (PDAC) reveals extensive glycan remodeling during epithelial-mesenchymal transition (EMT) and demonstrates that basal-like PDAC cells selectively reinforce interactions with lectin receptors expressed on innate immune cells, particularly tumor-associated macrophages. These EMT-driven glycan-lectin circuits are proposed to transmit immunosuppressive signals within the TME and show a strong association with clinical outcomes. Collectively, these advances highlight glycans as active mediators, rather than solely passive tumor markers of immune regulation, and provide a conceptual framework for understanding and potentially exploiting glycan-mediated immune regulation in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.